<DOC>
	<DOCNO>NCT02704858</DOCNO>
	<brief_summary>NEO100-01 Phase 1/2A study monoterpene , perillyl alcohol ( NEO100 ) patient recurrent glioblastoma . NEO100 deliver four time day intranasal administration use nebulizer nasal mask 6 month . Four escalate dos evaluate tolerability , maximum tolerate dose extended 2A phase total 25 patient . There concurrent control . This first nasal administration US , prior oral study perillyl alcohol prove ineffective . Nasal administration perillyl alcohol on-going Brazil</brief_summary>
	<brief_title>Safety Efficacy Study Recurrent Grade IV Glioma</brief_title>
	<detailed_description>Perillyl alcohol previously test 15 clinical study &gt; 600 subject This include 13 study 255 subject use oral administration sponsor National Cancer Institute two study &gt; 350 subject use intranasal administration Brazil . NEO100 highly purify ( &gt; 99 % ) form perillyl alcohol . Studies Brazil suggest improve survival patient recurrent glioblastoma . Doses 96 mg qid , 144mg qid , 192mg qid , 288 mg qid administer intranasally patient recurrent GBM 6 month , disease progression death . From 3 6 patient evaluate first cycle ( 28 day ) MTD reach . MRI gadolinium base line , begin even cycle . A total 25 patient treated MTD . PK study conduct Phase 1 first dosing , first dose 3rd cycle .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Perilla alcohol</mesh_term>
	<criteria>Radiographicallyconfirmed progression recurrent Grade IV glioma , must stable dose steroid least five day Must fail previous radiation temozolomide treatment . Must ECOG performance status 0 2 , KPS ≥ 60 . Must expect survival least three month . Must willing provide blood sample pharmacokinetic study Must adequate organ marrow function Female patient childbearing potential male patient must agree use adequate contraception Must ability understand , willingness sign , write informed consent . Patient surgery within one week prior study entry , chemotherapy within last four week Patient prior treatment bevacizumab , FDA approve chemotherapy except temozolomide . Patient one recurrence progression tumor . ·Patient receive investigational agent . Patient history allergic reaction attribute perillyl alcohol . Patient uncontrolled intercurrent illness Patient history new diagnosis treatment cancer malignant glioma within five year prior start study , except basal cell carcinoma squamous cell carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent glioblastoma</keyword>
	<keyword>recurrent GBM</keyword>
</DOC>